The group will integrate IDT's oligo synthesis technology with 3CR's PCR Allele Competitive Extension (PACE) Genotyping Master Mix and expertise in developing assays.
IDT and Beijing-based ChosenMed plan to develop large pan-cancer panels as part of the Cancer Genome Atlas of China.
Editas exclusively licensed the new enzyme, Alt-R Cas12a (Cpf1) Ultra, a mutant of Acidaminococcus sp. BV3L6 Cas12a (Cpf1), from IDT for therapeutic applications.
Early-access users have used IDT's rhAmpSeq technology to create genetic marker maps for plants and to validate off target events in gene editing.
CRISPR technology has made its way around the world, but in the wake of the He Jiankui controversy, the industry is asking what recourse it has against misuse.
The assay has been developed for research purposes, as a higher-throughput and lower-cost alternative to similar commercially available tests.
Within diagnostics, Beckman Coulter saw core revenue growth in the low-single digits, while Cepheid was up in the double digits for the quarter.
The company's Life Sciences segment was up 17 percent year over year, while its Diagnostics business grew 8 percent.
IDT will operate as a standalone company within Danaher's Life Sciences segment after the close of the deal, which is expected to occur in mid-2018.
Aldevron will manufacture IDT's patented S. pyogenes HiFi Cas9 mutant for research, clinical, and commercial uses.
The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.
In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.
MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.
In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.